Similarly, Mozas and coworkers [18] in Spain looked at the efficiency of different tumor markers (CA-125, carcinoembryonic antigen, CA-15.3, CA-19.9) and insulin-like growth factor I (IGF-I) measurements as a screening procedure for acute PID, and found no differences in the levels of CA-15.3, CA-19.9, carcinoembryonic antigen and IGF-I between three groups studied. The gene discussed is CEACAM5; the disease is neoplasm.